The PCR-produced linear DNA is expected to accelerate vaccine production.
Applied DNA Sciences has extended its partnership with Takis Biotech to include the development of a vaccine for 2019-nCoV coronavirus.
LineaRx, a subsidiary of Applied DNA, will work with Takis Biotech on preclinical development of a linear DNA vaccine based on polymerase chain reaction (PCR).
The PCR-produced DNA could accelerate vaccine production, avoid antibiotics and associated resistance genes and provide simple design, as well as deliver strong immunogenicity.
Applied DNA adds that a linear DNA vaccine gene will be sufficient even without integration into the patient’s genome.
